GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NVO) » Definitions » Cash from Discontinued Operating Activities

Novo Nordisk AS (MEX:NVO) Cash from Discontinued Operating Activities : MXN0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Novo Nordisk AS Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Novo Nordisk AS's Cash from Discontinued Operating Activities for the three months ended in Sep. 2024 was MXN0 Mil. It means Novo Nordisk AS received MXN0 Mil from discontinued investing activities. Novo Nordisk AS's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 was MXN0 Mil.

Novo Nordisk AS Cash from Discontinued Operating Activities Historical Data

The historical data trend for Novo Nordisk AS's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cash from Discontinued Operating Activities Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novo Nordisk AS Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NVO) » Definitions » Cash from Discontinued Operating Activities
Comparable Companies
OCSE:HLUN A OCSE:STENO LLY JNJ ABBV MRK XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN GILD BMY TSE:4519 LSE:GSK TSE:4568 SHSE:600276 TSE:4578 BIIB
Traded in Other Exchanges
NONOF:USA NVO:USA NOVOB:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NOV:Bulgaria NNO2:Austria
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
Website
https://www.novonordisk.com
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.